Laquinimod, Huntington's disease, and disease modification

Lancet Neurol. 2024 Mar;23(3):220-221. doi: 10.1016/S1474-4422(24)00001-2. Epub 2024 Jan 24.

Author

Tiago A Mestre¹

Affiliation

¹ Ottawa Hospital Research Institute; University of Ottawa Brain and Mind Research Institute; Division of Neurology, Department of Medicine, University of Ottawa, The Ottawa Hospital Ottawa, Ottawa, ON K1Y 4E9, Canada. Electronic address: tmestre@toh.ca.

PMID: 38280390
DOI: 10.1016/S1474-4422(24)00001-2

No abstract available

MeSH terms

Humans
Huntington Disease* / drug therapy
Quinolones* / pharmacology
Quinolones* / therapeutic use

Substances

laquinimod
Quinolones